DaVita HealthCare Partners Inc. (NYSE:DVA)‘s stock had its “hold” rating reaffirmed by Bank of America Corp. in a report issued on Monday. They presently have a $68.00 target price on the stock. Bank of America Corp.’s price objective indicates a potential upside of 10.53% from the company’s current price.

Several other research analysts also recently issued reports on the stock. Jefferies Group reiterated a “buy” rating and issued a $70.00 target price (down previously from $86.00) on shares of DaVita HealthCare Partners in a research note on Saturday. Zacks Investment Research upgraded shares of DaVita HealthCare Partners from a “strong sell” rating to a “hold” rating in a research note on Friday, November 4th. Wells Fargo & Co. reiterated an “outperform” rating on shares of DaVita HealthCare Partners in a research note on Tuesday, November 1st. SunTrust Banks Inc. set a $66.00 target price on shares of DaVita HealthCare Partners and gave the stock a “hold” rating in a research note on Thursday, October 13th. Finally, Raymond James Financial Inc. upgraded shares of DaVita HealthCare Partners from a “market perform” rating to an “outperform” rating and set a $75.00 target price on the stock in a research note on Tuesday, September 20th. Nine analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $74.42.

Analyst Recommendations for DaVita HealthCare Partners (NYSE:DVA)

DaVita HealthCare Partners (NYSE:DVA) traded up 0.81% on Monday, reaching $62.02. 772,842 shares of the company traded hands. The stock has a market capitalization of $12.24 billion, a price-to-earnings ratio of 18.08 and a beta of 1.00. The stock’s 50-day moving average is $60.71 and its 200-day moving average is $69.70. DaVita HealthCare Partners has a 1-year low of $54.50 and a 1-year high of $78.77.

DaVita HealthCare Partners (NYSE:DVA) last issued its earnings results on Wednesday, November 2nd. The company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.02. The firm had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.72 billion. DaVita HealthCare Partners had a net margin of 4.92% and a return on equity of 16.16%. The business’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.12 earnings per share. Equities research analysts expect that DaVita HealthCare Partners will post $3.78 EPS for the current year.

A number of hedge funds have recently made changes to their positions in DVA. Founders Capital Management LLC boosted its stake in shares of DaVita HealthCare Partners by 0.6% in the second quarter. Founders Capital Management LLC now owns 82,384 shares of the company’s stock worth $6,370,000 after buying an additional 510 shares in the last quarter. Creative Planning raised its position in DaVita HealthCare Partners by 46.8% in the second quarter. Creative Planning now owns 3,960 shares of the company’s stock worth $306,000 after buying an additional 1,262 shares during the last quarter. Atria Investments LLC purchased a new position in DaVita HealthCare Partners during the second quarter worth $352,000. Northstar Group Inc. raised its position in DaVita HealthCare Partners by 6.2% in the second quarter. Northstar Group Inc. now owns 12,050 shares of the company’s stock worth $932,000 after buying an additional 700 shares during the last quarter. Finally, Exxonmobil Investment Management Inc. TX raised its position in DaVita HealthCare Partners by 4.7% in the second quarter. Exxonmobil Investment Management Inc. TX now owns 42,228 shares of the company’s stock worth $3,265,000 after buying an additional 1,883 shares during the last quarter. 86.14% of the stock is owned by institutional investors and hedge funds.

DaVita HealthCare Partners Company Profile

DaVita Inc, formerly DaVita HealthCare Partners Inc, is a provider of kidney care services. The Company operates Kidney Care division and HealthCare Partners (HCP) division. The Company’s segments include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives.

5 Day Chart for NYSE:DVA

Receive News & Stock Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related stocks with our FREE daily email newsletter.